Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo Agrees to Exempt PD-1/PD-L1, JAK Classes from Spillover Re-Pricing
March 25, 2024
-
REGULATORY Xocova’s Price to Remain Intact after Full Approval, No Change in Clinical Positioning
March 25, 2024
-
REGULATORY Pharma Regulation Panel Wraps Up Debate, Report to Be Finalized Soon
March 22, 2024
-
REGULATORY Japan Resumes Debate on Rx-to-OTC Switch of PPIs after Over 5 Years
March 22, 2024
-
BUSINESS Will Kyowa Kirin’s Eye Drops for nAMD Replace Intraocular Injections? PII Now Underway
March 21, 2024
-
BUSINESS Meiji’s Bivalent COVID Jab Hits Primary Goal in PIII Omicron Trial; New Strains Eyed
March 21, 2024
-
REGULATORY Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
March 19, 2024
-
BUSINESS FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
-
BUSINESS Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
March 18, 2024
-
REGULATORY Japan to Present Class-by-Class Generic Shares to Hit New Goals: Minister
March 18, 2024
-
REGULATORY Japan Begins Discussions on RSV Vaccines for National Immunization Program
March 15, 2024
-
BUSINESS Takeda Settles on Lower Pay Hike than 2023; Union Group Says Pharma Labor Talks Tougher than Others
March 15, 2024
-
REGULATORY PD-1/PD-L1, JAK Drugs to Be Exempt from Spillover Price Cuts: Chuikyo
March 14, 2024
-
REGULATORY Lagevrio, Kerendia Braced for Price Cuts after Cost-Effectiveness Assessment
March 14, 2024
-
REGULATORY Japan Needs Systemic Reform to Balance Universal Coverage and Access to Pricey Meds: LDP Health Affairs Chief
March 13, 2024
-
COMMENTARY With So Many of Its Demands Met, How Will Industry Oppose Off-Year Price Revisions in FY2025?
March 12, 2024
-
REGULATORY PMDA Looks to Rev Up Pediatric and Orphan Drug Initiatives in Next 5-Year Plan: Chief
March 11, 2024
-
ACADEMIA Expert Says RSV Shots Will Have Significant Clinical Impact, Urges Public Funding and NIP Inclusion
March 8, 2024
-
BUSINESS Eisai CEO Confident in Leqembi Uptake, Says 90% of US Hospital Targets to Adopt Med by March-End
March 8, 2024
-
BUSINESS Majority of Drug Makers “Somewhat Satisfied” with FY2024 Revision: Poll
March 7, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…